The FDA approved Tauklarify on Aug. 14, 2026 for brain PET scans in adults with cognitive impairment evaluated for Alzheimer's.
For younger-onset families, the change adds a second tau-imaging choice that can sharpen staging and care decisions, with broad access still to come. Tau PET imaging is a brain scan that lights up tau tangles, twisted proteins tied to Alzheimer's damage. Tauklarify, or florquinitau F 18 injection, identifies that tangle pathology during the diagnostic workup, according to the FDA approval notice from Lantheus.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from Lantheus — Use this primary source to verify the official announcement.
- Read the official guidance from Neurologylive — Use this primary source to verify the official guidance.
Table of Contents
- What does this scan add?
- How well does it work?
- Why does it matter for younger-onset families?
- What should you ask your clinic now?
What does this scan add?
Tauklarify joins one earlier FDA-approved tau tracer, Lilly's Tauvid. It binds tau tangles directly and complements amyloid PET rather than replacing it, according to the Society of Nuclear Medicine and Molecular Imaging in its approval summary. That pairing matters in practice.
Amyloid scans show plaques that can appear early. Tau scans show tangles that track more closely with symptoms and disease stage. The drug has a long research history as MK-6240. Developer NeurologyLive reports it had fast-track status and prior use in nearly 100 trials before approval in its approval report.
How well does it work?
Approval rested on two studies using blinded expert readers. Positive agreement ran 68% to 88% across five readers, while negative agreement ran 93% to 99%. Readers also agreed strongly with each other.
Kappa scores were 0.92 and 0.86, and safety data covered 1,734 people. In head-to-head research, MK-6240 distinguished Alzheimer-related impairment better than flortaucipir, with an AUC of 0.93 versus 0.86. That sharper signal can help in complex or atypical cases and in selecting candidates for anti-amyloid drugs.
Why does it matter for younger-onset families?
Younger-onset Alzheimer's often brings confusing symptoms, work disruption, and competing diagnoses. A clearer picture of tau burden can help families and clinicians stage impairment, including at early stages. It can also focus treatment conversations.
Tau level and spread help doctors judge whether symptoms fit Alzheimer's and whether referral for amyloid-targeted therapy makes sense. Accuracy has limits early in disease. Families should treat the scan as one strong piece of evidence, not the whole answer.
What should you ask your clinic now?
Lantheus has not set broad commercial availability, and rollout timing and coverage remain undisclosed. Families should ask directly about access and referral.
A positive scan alone does not diagnose Alzheimer's. A negative scan does not rule out tangles, safety and effectiveness are not established for non-Alzheimer tau disorders, and accuracy may fall earlier in disease.
- Is tau PET offered here, or is referral to an imaging center needed?
- Do my symptoms and prior tests meet the use criteria?
- How will tau results combine with amyloid tests, MRI, and cognitive testing?
- What is the out-of-pocket cost and prior-authorization process?
- How soon will results reach our care team?
You Might Also Like
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Changed and What Comes Next for Younger-Onset Alzheimer’s Families
